|
17 Sep 2025 |
Biocon
|
Consensus Share Price Target
|
360.20 |
380.11 |
- |
5.53 |
buy
|
|
|
|
|
28 Apr 2016
|
Biocon
|
ICICI Securities Limited
|
360.20
|
544.00
|
575.65
(-37.43%)
|
Pre-Bonus/
Split |
Hold
|
|
|
|
|
28 Apr 2016
|
Biocon
|
Phillip Capital
|
360.20
|
600.00
|
575.65
(-37.43%)
|
Target met |
Buy
|
|
|
9 Continued robust sales growth in Syngene (+32%) and recovery in biopharma sales (+9%).Maintainedstrongoperatingperformancedespite78%jumpinR&D;spend 9 ExpectstolaunchGlargineinJapaninH1FY17andregulatoryfilingoffourbiosimilars...
|
|
18 Mar 2016
|
Biocon
|
Phillip Capital
|
360.20
|
600.00
|
459.30
(-21.58%)
|
Target met |
Buy
|
|
|
BIOS enteredinto an agreement withLaboratorios PiSA S.A. de C.V(PiSA) of Mexico for the codevelopment and commercialisation of generic recombinant human insulin (rh insulin)fortheUSmarket.Webelievethedevelopmentisstrategic,asBIOScanusePiSA's...
|
|
25 Jan 2016
|
Biocon
|
ICICI Securities Limited
|
360.20
|
510.00
|
489.05
(-26.35%)
|
Pre-Bonus/
Split |
Hold
|
|
|
|
|
25 Jan 2016
|
Biocon
|
Phillip Capital
|
360.20
|
600.00
|
489.05
(-26.35%)
|
Target met |
Buy
|
|
|
Continued robust sales growth in Syngene (+23%) was offset by muted sales performanceinbiopharmaandbrandedformulations 9 Reportedencouragingdataforitsnoveldrugoralinsulin(Tregopil)inPhase1clinical...
|
|
22 Oct 2015
|
Biocon
|
Phillip Capital
|
360.20
|
575.00
|
452.50
(-20.40%)
|
Target met |
Buy
|
|
|
9 Biocon expects to file commercialisation application for its biosimilars (Glargine, Trastuzumab,Pegfilgrastimandinsulin)intheUSandEuropeinFY17 Keyhighlights:Modest10%salesgrowthtoRs8.25bn(estimatedRs8.44bn),duetoslow...
|
|
21 Oct 2015
|
Biocon
|
Karvy
|
360.20
|
531.00
|
452.50
(-20.40%)
|
Target met |
Buy
|
|
|
Biosimilars On Track - Base Business Margin Growth: yyProgress in R&D: Biocon's biosimilars and novel molecules program is on track as was expected. The company is analyzing the study results of IN-105 and renamed it as Insulin Tregopil as INN granted by WHO. The company has taken an mpairment loss on account of US rights of Itolizumab as US access which might not be expeditious. The other phase-III studies are progressing with Glargine patient recruitment completed and nearing completion in Pegfilgrastim and Trastuzumab. The R&D expenditure increased by 62% YoY in Q2FY16.
|
|
15 Oct 2015
|
Biocon
|
Karvy
|
360.20
|
527.00
|
440.30
(-18.19%)
|
Target met |
Buy
|
|
|
Betting big on Biosimilars: Facility in place - Regulatory and Clinical clearances remain: Eyeing a piece of the US$ 24 Bn biosimilars market by 2019 partnering Mylan, Biocon has 4 molecules in Global Phase-III clinical trials, 1 in RoW Phase-III trials and human insulin eyeing harmonized filings. The Malaysian facility, which will be the focal point for this segment, has commercialized and receivedMalaysian approval, a first in a series of approvals required in next 12-18 months.
|
|
27 Jul 2015
|
Biocon
|
Phillip Capital
|
360.20
|
491.00
|
459.95
(-21.69%)
|
Target met |
Buy
|
|
|
to deliver >20% earning CAGR over FY1517 led by (1) commercialisation of its Malaysia facility from Q4FY16, (2) resumption of Fidaxomicin supply contract with Merck, (3) commercial launch of Glargin (launched in Mexico and Columbia, approved in 18 other...
|
|
04 May 2015
|
Biocon
|
Phillip Capital
|
360.20
|
491.00
|
453.90
(-20.64%)
|
Target met |
Buy
|
|
|
|